Alltrna's ML-driven platform optimizes sequence and modifications from natural tRNAs to significantly increase premature termination codon (PTC) readthrough First Alltrna-engineered tRNA ...

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

Coronaviruses not only use the machinery of the human cells they infect: they modify them to achieve optimal conditions to ...

Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...

The various identities of cells, whether they are in the brain, heart, kidney, or any other tissue, are defined by the genes they expressed. In basic terms, the genes that are active in a cell are ...

tRNAs have a distinct cloverleaf secondary structure and an L-shaped tertiary structure. The cloverleaf structure is formed by the folding of the single-stranded tRNA molecule, which is typically ...

Alltrna's ML-driven platform has screened billions of tRNA molecules in silico to precisely engineer therapeutic properties driven by tRNA sequence and chemical modifications Alltrna presents data ...